RXRX · CIK 0001601830 · operating
Recursion Pharmaceuticals is a clinical-stage biotechnology company that applies computational biology, chemistry, automation, and data science to accelerate drug discovery and development. The company integrates technological platforms across multiple disciplines to identify and validate drug candidates across oncology and genetic disease indications. Its pipeline includes five candidates in Phase 1/2 clinical development: REC-4881 for familial adenomatous polyposis, REC-617 and REC-1245 for solid tumors, REC-3565 for relapsed or refractory B-cell malignancies, and REC-4539, an LSD1 inhibitor for solid tumors and hematologic malignancies. The company also maintains preclinical programs including REC-7735 for hormone receptor-positive breast cancer and REC-102 for hypophosphatasia.
Recursion has established strategic collaborations with major pharmaceutical companies including Roche & Genentech, Sanofi, Bayer, Takeda Pharmaceutical, and Tempus. These partnerships provide development support and potential revenue opportunities through milestone payments and royalties. The company operates primarily from its headquarters in Salt Lake City, Utah, with additional operations in the United Kingdom, and employed approximately 600 full-time employees.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.44 | $-1.44 | +14.8% | |
| 2024 | $-1.69 | $-1.69 | -7.0% | |
| 2023 | $-1.58 | $-1.58 | -16.2% | |
| 2022 | $-1.36 | $-1.36 | +8.7% | |
| 2021 | $-1.49 | $-1.49 | — |